IFNG and Cowden disease: A prior study found that administering two Fontolizumab doses, an anti-IFN-γ antibody that disrupts Th1 polarization andmacrophage, monocyte, and natural killer cell activation, to patients with active CD led to higher clinical response rates and remission induction compared to placebo [40].